Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis
Approximately 45% of anaplastic thyroid cancer (ATC) patients harbor a BRAF mutation and are eligible for target therapy (TT) with BRAF and MEK inhibitors (BRAFi/MEKi), nevertheless, few data advocate for this. Hence, we've conducted a systematic review and meta-analysis investigating the effec...
Saved in:
Published in | Endocrine |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
06.05.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Approximately 45% of anaplastic thyroid cancer (ATC) patients harbor a BRAF
mutation and are eligible for target therapy (TT) with BRAF and MEK inhibitors (BRAFi/MEKi), nevertheless, few data advocate for this. Hence, we've conducted a systematic review and meta-analysis investigating the effectiveness and safety of BRAFi/MEKi in BRAF
ATC patients.
PubMed, Embase, and the Cochrane Library were systematically searched for BRAFi/MEKi TT in BRAF
ATC patients. Outcomes included objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), duration of response (DOR) and adverse events (AEs).
Nine studies with 168 patients were included. Median follow-up ranged from 2.0 to 47.9 months. 75% of patients had stage IVc. In a pooled analysis, ORR was 68.15% (95% CI 55.31-80.99, I
= 47%) and DCR was 85.39% (95% CI 78.10-92.68, I
= 0), with a median DOR of 14.4 months (95% CI 4.6-14.4) and a median PFS of 6.7 months (95% CI 4.7-34.2). Moreover, 1-year OS rate was 64.97% (95% CI 48.76-81.17, I
= 84%) and 2-years OS rate was 52.08% (95% CI 35.71-68.45, I
= 79%). Subgroup analysis showed patients in the neoadjuvant setting had higher rates of 1 and 2-years OS and observational studies tended to report higher rates of ORR than clinical trials. No new or unexpected adverse events were found.
Our study demonstrated BRAFi/MEKi have a decent activity for BRAF
ATC patients, especially in the neoadjuvant setting, with a tolerable safety profile. However, further clinical trials are warranted to investigate these findings. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1559-0100 1559-0100 |
DOI: | 10.1007/s12020-024-03845-w |